Arformoterol Tartrate Solution
Product Images NDC 69097-168

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 69097-168). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 01

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 02

The text appears to be a graph showing the mean change in FEV1 over time for a clinical trial at week 0, with time measured in hours postdose and the mean change from baseline FEV in liters.*

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 03

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 04

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 05

The text is describing a clinical trial involving a medication called arformoterol tartrate. The trial included 141 participants (ITT n=141) and was conducted to compare the effects of the medication to a placebo (ITT n=143). The baseline FEV (forced expiratory volume) for the placebo group was 1.20 L, but there is no data included for the baseline FEV of the group receiving arformoterol tartrate. The medication was administered twice a day at a dose of 15 micrograms.*

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 06

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 07

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 08

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 09

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 10

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 11

Arformoterol Tartrate Inhalation Solution is a prescription drug that comes in 2 mL vials, each containing 15 mg (expressed as an arformoterol) of arformoterol. The unused vials should be returned to and stored in the pouch after opening. The medication should be kept away from the reach of children. The unit dose vials should be protected from light and excessive heat. The medication must be used under the guidance of a physician and not recommended for others. This drug is manufactured by Cipla Ltd.*

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 12

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 13

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 14

Arformoterol Tartrate Inhalation Solution is a unit-dose vial containing 15 meg of arformoterol in a sterile, isotonic saline solution that should be kept away from light and excessive heat. The vials can be stored in a refrigerator or at room temperature for up to 6 weeks. Patients should discard the solution if it is not colorless and use only as directed by their physician. The product is manufactured by Cipla Ltd in India and distributed in the US by G USA, Inc.*

FDA Label Image

B4866add E9d7 4933 988a 256ecc149be9 15

Arformoterol Tartrate Inhalation Solution is a medication that is used for inhalation through the mouth to help treat shortness of breath and wheezing caused by chronic obstructive pulmonary disease (COPD). It is available in 15-microgram capsules and is sold in sterile, unit-dose vials that can be stored at room temperature or refrigerated for up to six weeks. The medication includes 30 sterile, 2-milliliter unit-dose vials in a foil pouch. The potency of the medication is expressed as arformoterol and it is manufactured by Cipla. The medication is available for prescription-only in the NDC 69097-168-53 lot.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.